We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Seems to be firming ready for a Surge higher. There is astronomical upside here over the coming few years and this weeks news has been fantastic !
https://endpts.com/in-starved-antibiotic-field-melinta-soars-as-fda-grants-speedy-drug-review/
Thank you Chris and Waterloo01...
I had a quick look at the DISARM 2019 act again and, on my quick read, it looked like it was effective (after public consultation) on the 1st of Oct 2020 - and providing 106% now, instead of 102%. I might have misunderstood it though? Link to the bill below..
https://www.isakson.senate.gov/public/_cache/files/244e41a8-9d38-4024-9783-a1511c133816/06-04-19%20DISARM%20116th%20Congress.pdf
Per waterloo01 from the other board:
Quick AGM update.
Lots of talk about the different approach to antibiotics, in going for both superiority and presenting the economic case. Many of the recent failures in the space have a lot to do with the fact most are going for equivalence/me too products.
There are only 8 antibiotics currently in phase 1-3 that are new mechanism if actions, RDZ being one of them
Are about 100 sites currently open (Clinical trials lists 2 but apparently is out of date). Results still planned mid 2021.
Barda relationship is good and possibility of some more from them but there is a funding gap which is estimated to be between $60m and $100m over 2 years.
Most likely this will be raised from equity and one has the feeling they have somethings lined up. Stressed point that last placing was at a premium, so hopefully that's repeated. Dungan continues to be supportive and likely to come in on any further raises.
Push and pull incentives are important, but because of their approach (superiority)they will build an economic case regardless. However the current bill going through US congress (Disarm) could make a massive difference as will pay hospital 102% of the cost of the drug (are other initiatives ongoing as well). Might this be the thing that will change the whole investment environment?
Still suggesting market could be worth $1bn US alone (they want to keep US rights but might other geographies be part of any funding?) and if adopted RDZ should save hospitals $3 bn a year.
Other antibiotics all going to plan.
So in short, an exciting future but further funding needed, but the end prize remains significant and ever more so as and when the investing community start to reinvest in the area (and Disarm act might be the thing that makes the difference here).
More if I remember. Good to meet the other investors.
I thought that this bit of news about additional funds would have put a rocket on the share price?Good old aim
What other news on the horizon??
Boom times ahead
Nice rns yesterday
Any thoughts of a potential buyout by one of the majors, with what`s on offer here at this stage, just a thought? GLA
Looking good again now hopefully.
RNS 12th June
"Recruitment of patients into the two Phase 3 clinical trials is ongoing, and the programme remains on-track for expected reporting of top-line data in H2 2021"...
We should get more updates on recruitment as the trial progresses.. - I'd hope at least
Perhaps should also mention as phase 3 results sound a while away but there will be news on other products in the pipeline currently on there Discuva platform.
GLA
Hi Stew200 Should be early 2021 although they have fast track status so hopefully earlier (-;
GLA
When will they be posted ?
Yes good news today and long term a truly terrific opportunity. Perhaps we might even see our DMD losses back. Keep the faith. Good luck.
The RNS was certainly positive and the US seem to have great confidence in the science, so fingers crossed for a decent move North, especially for the people who need this to work and SH`s alike. GLA
i would like to hope we can get back to the levels we were at last year before the crash, however i can't see it happening , i think like most on here i'm in a catch 22 position, can't afford to buy anymore and just looking to make the best of a very bad investment, damage limitation and a long few years ahead.
I wonder if we can get to the levels we got to a few years ago and are we expecting more news.
I think todays RNS may have got rid of 'The Elephant in the room' i.e. future funding & for the first the SP continues to rise (no profit taking).I only wish I had the funds to top up.
Agreed great call shows really re-emphasises how likely this is to succeed now! The sky is the limit here
yep, good call Christatrdg
Well looks like my gut feeling Monday was right ( see below) todays RNS is great news & demonstrates that there is additional support for the Phase 3 C-Diff trials which should extend the cash runway.
Monday post:
'Could we be in for a surprise RNS soon in which it is announced that Summit will receive further funding for their C-Diff trials based on recent articles for the need to combat diseases like C-Diff there was a final realisation that their drug must succeed & so funds provided.Just a thought.'
That’s greats news
'Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and Development Authority (‘BARDA’) has increased the total value of its award for the clinical and regulatory development of Summit’s precision antibiotic ridinilazole for the treatment of C. difficile infection (‘CDI’) to up to $63.7 million.'
http://www.globenewswire.com/news-release/2019/06/18/1870133/0/en/Increased-BARDA-Award-and-Option-Exercise.html
Thanks Chris - look forward to hearing how it goes, and as you say they can't really give any substantial updates without an RNS... hopefully we'll start seeing a recovery soon..